Oral Biologics & Biosimilar Drugs Global Market To Reach Value Of About $9 Billion In 2025

22 Oct, 2021

The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer. Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.

Global Oral Biologics & Biosimilar Drugs Market Size And Drivers:

The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to $4.1 billion in 2021 at a compound annual growth rate (CAGR) of 16.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $8.69 billion in 2025 at a CAGR of 21%. The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market.

Request For A Sample For The Global Oral Biologics & Biosimilar Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

Trends In The Global Oral Biologics & Biosimilar Drugs Market

The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. Following the trend, Mylan, a USA based pharmaceuticals company, in partnership with Biocon launched biosimilar insulin glargine named Semglee, in 2019 in Australia. Biocon is an Indian based biopharmaceutical company. In 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

Global Oral Biologics & Biosimilar Drugs Market Segments:
The global oral biologics & biosimilar drugs market is further segmented –
By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors,
By Disease: Asthma, Crohn'S Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The global oral biologics & biosimilar drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Oral Biologics & Biosimilar Drugs Market At:

https://www.thebusinessresearchcompany.com/report/oral-biologics--and--biosimilar-drugs-global-market-report

Oral Biologics & Biosimilar Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides oral biologics & biosimilar drugs market overviews, analyzes and forecasts market size and growth for the global oral biologics & biosimilar drugs market, oral biologics & biosimilar drugs market share, oral biologics & biosimilar drugs market players, oral biologics & biosimilar drugs market segments and geographies, oral biologics & biosimilar drugs market’s leading competitors’ revenues, profiles and market shares. The oral biologics & biosimilar drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.